We are happy to share we have received U.S. FDA IND clearance for #TRX103 in the treatment of patients with refractory Crohn's Disease. This represents the second IND Clearance for our #allogeneic #Tr1 #Treg cell therapy. We look forward to sharing more updates throughout the rest of the year as we tackle this devastating #autoimmune and #inflammatory disease. Read more here: https://lnkd.in/gvDyPEEv Maria Grazia Roncarolo Marco Londei Muhi Davis Viktoriya Megrabova James Adams Ryan Bjordahl Yu Alex Kato Daryl Humes Matthew Breton Lyndsey Young Jie Wei Leon Chen Liliana Nordbakk John T. Dimos, PhD Mario Costantini Sarah Hymowitz
Tr1X
Biotechnology Research
San Diego, California 2,686 followers
Engineering cures for patients with autoimmune & inflammatory diseases.
About us
Tr1X Inc. (pr. "Trix") is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases. The Company uses its proprietary platform for the generation of first-in-class cell therapy products aimed at rebalancing the immune system and restoring homeostasis, leading to long term tolerance. Tr1X is headquartered in La Jolla, CA.
- Website
-
https://www.tr1x.bio
External link for Tr1X
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Specialties
- immunology, immunotherapy, cell therapy, genetic engineering, biotechnology, autoimmune disease, inflammatory disease, research, T cells, and tolerance
Locations
-
Primary
Get directions
9310 Athena Circle
Suite 220
San Diego, California 92037, US
Employees at Tr1X
Updates
-
Today, we announced the successful dosing of our first #allogeneic #Tr1 #Treg cell therapy candidate, TRX103, in #GvHD prevention for patients undergoing #HSCT. We are pleased to report that the first patient had no severe adverse events, and that the #trial continues to enroll. We look forward to providing more updates soon. #celltherapy #autoimmune #inflammation Read more: https://lnkd.in/g9MbUfWP
-
Maria Grazia Roncarolo spent some time with the #biomarker newsletter folks last week, detailing her personal journey in discovering her passion for science, and her lifelong mission to cure #autoimmunity. She also speaks on her discovery of #tr1 #tregs and their applications in medicine and the #science of advancing #cell and #gene therapies from bench to clinic. Read more below! Dylan Neel Utsarga (Tito) Adhikary
Biomarker interview with Maria Grazia Roncarolo, Professor at Stanford University School of Medicine and co-founder, President/Head of R&D at Tr1X We discuss Dr. Roncarolo's training as a physician-scientist, and work on gene therapies for primary immunodeficiencies and immune tolerance. She walks us through her team's first isolation of the Tr1 regulatory cell from patients, and subsequent characterization at DNAX in 1997. As someone who has worked in the field for decades, she discusses the traditional barriers to cell therapy (both CAR-T and Tregs): including manufacturing, durability, efficacy and patient access. Lastly she covers the exciting work at Tr1X , and the allogeneic platform they are advancing to treat graft versus host disease, and other autoimmune conditions. Now in the clinic, they are testing the hypothesis that these cells can "reset" the immune system and promote endogenous Treg activation, and functional cures. #biomarker #biotech #immunology Utsarga (Tito) Adhikary David de Vries https://lnkd.in/ehWeBAV5
Lab Meeting: Maria Grazia Roncarolo
biomarker.substack.com
-
Our Director of Process Development and Manufacturing Matthew Breton shared some of our lessons learned and strategies for successful #allogeneic #celltherapy development with our friends and colleagues at Cell & Gene Therapy Insights https://lnkd.in/gZsStX6k #immunology #autoimmune #offtheshelf #cmc
Planning for success with an allogeneic Treg cell sourcing strategy
insights.bio
-
Tr1X has received FDA clearance for our IND application for TRX103, the first ever #allogeneic engineered Tr1 regulatory T cell therapy in the clinic. We are now focused delivering proof-of-concept data in Graft versus Host Disease (GvHD), while continuing our pipeline work for multiple autoimmune and inflammatory diseases with high unmet need. #Innovation #Biotech #CellTherapy #clinicaltrial Read more here: https://lnkd.in/gC6VtiSi
-
-
Our leadership team, including CEO Bill Lis and Scientific founder Maria Grazia Roncarolo sat down with Lei Lei Wu of Endpoints News to discuss our launch and plans to move into the clinic for multiple #autoimmune indications using our engineered Tr1 cells. https://lnkd.in/gtS6w5jz #transplant #treg #cellandgenetherapy
Graphite Bio co-founder debuts Treg cell therapy startup with $75M, aims to ‘trick’ immune system into resetting
https://endpts.com
-
Tr1X is proud to announce our $75 Million Series A Financing, led by The Column Group with participation from NEVA SGR & Alexandria Real Estate Equities, Inc.. This funding will propel us toward our goal of bringing universal allogeneic regulatory T (Treg) and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases. Discover more in our press release: https://lnkd.in/gTMJsmjz And stay connected with us to receive regular updates along our journey. #Biotech #SeriesAFinancing #AutoimmuneDisease #CellTherapy
-